It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren’s syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Karolinska Institutet, Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
2 Karolinska Institutet, Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
3 Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy (GRID:grid.414818.0) (ISNI:0000 0004 1757 8749)
4 Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France (GRID:grid.411766.3) (ISNI:0000 0004 0472 3249)
5 Université catholique de Louvain, Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X)
6 Centro Hospitalar do Porto, Porto, Portugal (GRID:grid.418340.a) (ISNI:0000 0004 0392 7039)
7 Hospital Universitario Marqués de Valdecilla, Servicio Cantabro de Salud, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262)
8 Institut d’Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic I Provicia, Barcelona, Spain (GRID:grid.10403.36)
9 Katholieke Universiteit Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
10 Klinikum der Universitaet zu Koeln, Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X)
11 Medizinische Hochschule Hannover, Hanover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
12 Medical University Vienna, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
13 Hospital Universitario Reina Sofía Córdoba, Servicio Andaluz de Salud, Córdoba, Spain (GRID:grid.411349.a) (ISNI:0000 0004 1771 4667)
14 Complejo hospitalario Universitario de Granada (Hospital Universitario San Cecilio), Servicio Andaluz de Salud, Granada, Spain (GRID:grid.459499.c)
15 Complejo hospitalario Universitario de Granada (Hospital Virgen de las Nieves), Servicio Andaluz de Salud, Granada, Spain (GRID:grid.459499.c)
16 Hospital Regional Universitario de Málaga, Servicio Andaluz de Salud, Málaga, Spain (GRID:grid.411457.2)
17 Università degli studi di Milano, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
18 Hospitaux Universitaires de Genève, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988)
19 University of Szeged, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
20 Charite, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
21 Andalusian Public Health System Biobank, Granada, Spain (GRID:grid.6363.0)
22 Karolinska Institutet, Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); GENYO, Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Government, Parque tecnolуgico de la salud, Granada, Spain (GRID:grid.470860.d) (ISNI:0000 0004 4677 7069)